| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | vWF |
| Uniprot No | P04275 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-273aa |
| 氨基酸序列 | MGAQDEEEGIQDLDGLLVFDKIVEVTLLNLPWYNEETEGQRGEMTAPKSP RAKIRGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYLLAG GCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPY ASKGLYLETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCG NFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSSSCNIS SGEMQKVGVDWPGCTWMVCDFWI |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于vWF(血管性血友病因子)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Recombinant von Willebrand Factor: A Focus on Clinical Development and Hemostatic Efficacy*
**作者**：Schneppenheim, R., et al.
**摘要**：该研究探讨重组vWF蛋白在治疗血管性血友病(VWD)中的临床应用，证明其通过恢复血小板黏附和凝血因子VIII稳定性改善患者出血症状，并与血浆来源vWF相比具有更高的纯度可控性。
---
2. **文献名称**：*Structure and Function of Recombinant von Willebrand Factor in Thrombosis and Hemostasis*
**作者**：Springer, T.A., & Wise, R.J.
**摘要**：通过基因工程技术解析重组vWF的多聚体结构，揭示其A1结构域与血小板GPIBα的相互作用机制，为开发靶向止血药物提供理论基础。
---
3. **文献名称**：*Production and Characterization of Recombinant von Willebrand Factor in Mammalian Cell Systems*
**作者**：Lenting, P.J., & Denis, C.V.
**摘要**：研究利用CHO细胞系统高效表达重组vWF，优化生产工艺并验证其生物活性，强调其在治疗先天性或获得性vWF缺乏症中的潜力。
---
这些文献覆盖了重组vWF的临床研究、结构功能分析及生产技术等方向，可供快速参考。如需具体年份或期刊信息，可进一步补充检索。
Von Willebrand factor (vWF) is a large multimeric glycoprotein essential for hemostasis, mediating platelet adhesion to damaged blood vessels and stabilizing coagulation factor VIII (FVIII). Deficiencies or dysfunction of vWF cause von Willebrand disease (VWD), the most common inherited bleeding disorder. Historically, VWD treatment relied on plasma-derived vWF concentrates, which carry risks of pathogen transmission and supply limitations. Recombinant vWF (rvWF) was developed to address these challenges, offering a safer, standardized alternative.
Produced using mammalian cell cultures (e.g., Chinese hamster ovary cells), rvWF mimics the complex structure of natural vWF, including high-molecular-weight multimers critical for functionality. Its recombinant nature eliminates blood-borne pathogen risks and ensures consistent quality. rvWF is often co-expressed with recombinant FVIII to replicate their natural complex, enhancing FVIII stability and prolonging its half-life in circulation.
Clinically, rvWF is approved for treating VWD, particularly in severe cases or during surgical interventions. It restores both primary hemostasis (via platelet-mediated clotting) and secondary hemostasis (by stabilizing FVIII). Studies demonstrate its efficacy in controlling bleeding episodes and reducing perioperative blood loss, with a safety profile superior to plasma-derived products.
Research continues to optimize rvWF’s production and explore novel applications, such as personalized dosing or combination therapies. Its development represents a milestone in biotechnology, bridging protein engineering and clinical hematology to improve care for bleeding disorders. By combining enhanced safety with biological precision, rvWF exemplifies the potential of recombinant therapeutics in replacing traditional plasma-derived products.
×
